Moderna is developing updated vaccines against the new subvariants of Omicron

The pharmaceutical and biotechnology company Moderna announced today that it is developing two updated vaccines against the Omicron variant of the coronavirus for the fall: one designed against the BA.1 subvariant and another against the BA.4 and BA.5 subvariants.

Vaccine makers including Moderna and Pfizer are developing updated vaccines against Omicron’s rapidly spreading BA.4 and BA.5 subvariants, which have been spreading in the United States in recent weeks.

The bivalent vaccines are designed to target two different variants of the coronavirus: the original one from 2020 and the newer ones brought to the fore by Omicron.

According to Moderna, new clinical data for the mRNA-1273.214 vaccine it is developing against the BA.1 variant showed significantly higher neutralizing antibody responses against the rapidly spreading BA.4 and BA.5 compared to the current booster doses.

The company’s second vaccine, mRNA-1273.222, targets the BA.4/5 strains and is being developed in accordance with recent US Food and Drug Administration (FDA) recommendations.

Source: Capital

You may also like

Shiba Inu price analysis
Top News
David

Shiba Inu price analysis

At the time of publication, Shiba Inu (Shib) is traded at $ 0.00001282. The short-term rise in the price of